diagnosis meta-analysis urinary bladder urine biomarkers urothelial carcinoma BioScience Corp. Norihiko Masuda Osamu Ogawa Meyeon Park Alvin Y Liu Yunfeng Dai Landon Kozai Hideki Furuya Yair Lotan and Takashi Kobayashi declare that they have no conflicts of interest.

Cystectomy/*methods Humans Organ Sparing Treatments/*methods Treatment Outcome Urinary Bladder Neoplasms/*surgery Bladder preservation High-grade non-muscle-invasive bladder cancer Meta-analysis Radical cystectomy PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*Genetic Association Studies *Genetic Predisposition to Disease Genotype Glutathione Transferase/*genetics Humans Odds Ratio *Polymorphism Genetic Publication Bias Risk Urinary Bladder Neoplasms/*genetics Bladder cancer Gstm1 Gstp1 Gstt1 Gene polymorphism Meta-analysis PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Female Humans Male Prospective Studies *Quality of Life Urinary Bladder Neoplasms/drug therapy/*psychology/radiotherapy Bladder cancer Chemotherapy Muscle-invasive bladder cancer Quality of life Urothelial cancer PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Urinary bladder cancer characteristics prognosis review conflicts of interest with respect to the research authorship and/or publication of this article.

Bladder cancer Pd-1 Pd-l1 atezolizumab avelumab biomarkers durvalumab immunotherapy nivolumab pembrolizumab Urogen licenses/patents: University of Colorado research support: Medivation/Astellas stockholder in: Aurora Oncology PrecisionProfile other: IOS Press (editorial responsibilities compensated).The other authors report no conflicts of interest.

*Cystectomy *Health Status Humans Patient Education as Topic/*methods Preoperative Care/*methods Relaxation Therapy/*methods Urinary Bladder Neoplasms/*surgery Bladder cancer Cystectomy Supportive intervention Systematic review PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cystectomy Humans Procedures and Techniques Utilization/*statistics & numerical data Prospective Studies Retrospective Studies Risk Assessment Urinary Bladder Neoplasms/*surgery Predictors Radical cystectomy Use Utilization interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Carcinoma Transitional Cell/epidemiology/*surgery *Cystectomy Humans Kidney Neoplasms/*epidemiology Neoplasms Second Primary/*epidemiology Ureteral Neoplasms/*epidemiology Urethral Neoplasms/*epidemiology Urinary Bladder Neoplasms/*surgery Bladder cancer Radical cystectomy Recurrence Remnant Upper urinary tract Urethra Urothelium including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

bladder cancer chemotherapy cystectomy muscle-invasive systematic review of interest.

Biomarkers Tumor/*urine Fibronectins/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/urine Biomarker Bladder cancer Diagnosis Meta-analysis Urine fibronectin standards of institutional and international research committee this article is based on previous published studies thus it does not contain any studies with human participants or animals. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Asian People/genetics Biomarkers Tumor/*blood/urine Cystoscopy/adverse effects Humans MicroRNAs/*blood Neoplasm Staging Nuclear Proteins/urine Odds Ratio ROC Curve Regression Analysis Sensitivity and Specificity Urinalysis/methods Urinary Bladder Neoplasms/*blood/diagnosis/*genetics/urine Bladder cancer Diagnosis Meta-analysis miRNA authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Clinical Decision-Making Cystectomy/*methods Cytoreduction Surgical Procedures/methods Humans *Neoplasm Metastasis/pathology/therapy Practice Guidelines as Topic Treatment Outcome *Urinary Bladder Neoplasms/pathology/surgery Bladder cancer Lymph node dissection Lymph node metastasis Metastasectomy Metastatic bladder cancer Surgery interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Critical Pathways Cystectomy/*methods/rehabilitation Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology *Standard of Care Urinary Bladder Neoplasms/*surgery Urinary Diversion/*methods/rehabilitation Clinical pathways Collaborative care Cystectomy Enhanced recovery Fast track including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Kaplan-Meier Estimate Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Odds Ratio Prognosis Publication Bias Urinary Bladder Neoplasms/*mortality/*pathology/therapy histological variants squamous differentiation urothelial carcinoma of the bladder including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.